Bispecific Antibodies for Triple Negative Breast Cancer
- 1 February 2021
- journal article
- review article
- Published by Elsevier in Trends in Cancer
- Vol. 7 (2) , 162-173
Abstract
No abstract availableKeywords
Funding Information
- Johnson and Johnson Pharmaceutical Research and Development
This publication has 71 references indexed in Scilit:
- Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patientsMedical Oncology, 2013
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- Profiling phospho-signaling networks in breast cancer using reverse-phase protein arraysOncogene, 2012
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Safety of biologics, lessons learnt from TGN1412Current Opinion in Biotechnology, 2009
- Bispecific T-Cell Engaging Antibodies for Cancer TherapyCancer Research, 2009
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Activated T-Cell and Bispecific Antibody Immunotherapy for High-Risk Breast CancerActa Haematologica, 2001
- Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu + TumorsJournal of Hematotherapy & Stem Cell Research, 2001
- Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re‐filling of the lytic granules and secretion of lytic proteins via a non‐granule pathwayEuropean Journal of Immunology, 1995